NextCure
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9000 Virginia Manor Rd Ste 200, Beltsvil...Phone Number
(240) 399-4900Website
www.nextcure.comRevenue
$27.7 MillionStock Symbol
NXTCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NextCure
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.Explore more
NextCure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NextCure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NextCure
Earning: See what the market has to say on NextCure recently announced quarterly report
Click to see if NextCure had a recent Job posting/layoffs
Check out if NextCure is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NextCure has new funding data
Check if NextCure has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
NextCure, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when NextCure launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to NextCure
Compare insights from companies similar to NextCure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NextCure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NextCure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NextCure.
NextCure financials insights
Gather financial insights about NextCure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$67M
2019
Stock Offering
$86.3M
Stock Offering
$150M
2025
Other Financing Round
$21.5M
NextCure Tech Stack
A closer look at the technologies used by NextCure
Most Recent Scoops
Open Position
Open Position
Open Position
Earnings
NextCure has reported a net loss of $55.8 million for FY 2025, compared to $55.7 million in Q1 2025.
Earnings, Finance
Open Position
NextCure News & Media
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avere Therapeutics. Click here to learn how to join our investigation and obtain...NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapyNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antiNextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 AM...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NextCure
Sign Up For FreeTo access detailed company insights
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.... Read More
